Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam

IV Meloxicam Achieves Primary Endpoint in First of Two Pivotal Trials
Fifteen of Nineteen Secondary Endpoints Also Met
Management to Host Conference Call and Webcast Today at 5:00 PM ET
 
MALVERN, Pa., July 26, 2016  -- Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced positive results from its Phase III clinical trial evaluating intravenous (IV) meloxicam (N1539) for the treatment of acute postoperative pain in patients following bunionectomy surgery.  In the trial, IV meloxicam achieved the primary endpoint of a statistically significant difference in Summed Pain Intensity Difference (SPID) over the first 48 hours (SPID48) compared to placebo.
Read more: Recro Pharma Inc ( REPH )

Critical Elements (TSXV: CRE) and Ionic to Explore Valiquette and Amiral Lithium Properties in Quebec 

MONTREAL, QUEBEC--(Jul 18, 2016) - Critical Elements Corporation ("Critical Elements" or the "Company") (TSX VENTURE:CRE)(CRECF)(F12.F) and Ionic Power Corp. ("Ionic") are pleased to announce that Critical Elements and Ionic have entered into an option agreement ("Agreement") that gives Ionic the right to acquire up to a 75% interest in the Valiquette and Amiral projects, located south-west to the Nemaska Lithium Whabouchi Deposit.
 
"The Valiquette and Amiral projects represent a great opportunity for Ionic, Critical Elements and the shareholders of both entities."
 
"This option agreement with Ionic will allow the Valiquette and Amiral properties to be explored in detail for a Lithium Pegmatite discovery. Critical Elements is currently focused on the development of its Rose lithium-tantalum project. With Ionic farming into the Valiquette and Amiral projects, shareholders of both companies will be able to benefit from successful exploration of a highly prospective project," stated Jean-Sébastien Lavallée, President and CEO, Critical Elements.
Read more: Critical Elements Corporation ( CRE )

Helius Medical Announces Results from a Case Series of Subjects with Advanced MS

NEWTOWN, Pa.-- Helius Medical Technologies, Inc. (TSX: HSM, HSM.S, OTCQB: HSDT) ("Helius" or the "Company") is pleased to announce the results of a case series of individuals with advanced symptoms of Multiple Sclerosis (MS) treated with PoNS™ Therapy.
 
This study was performed at TCNL1, University of Wisconsin, Madison and the data was presented at the 2016, Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).
 
Six subjects with advanced MS (Expanded Disability Status Scale (EDSS)2 scores ranging from 6.5 to 7.5) were enrolled in a six-month pilot study. Subjects were trained in PoNS™ Therapy which combines use of the prototype PoNS™ device with physical training in balance, gait, movement and postural stability. Results demonstrated improvements in physical, cognitive and quality of life parameters. The demanding training regimen also resulted in significant real life improvements such as re-adopting a walker for community mobility, decreased fatigue, increased independence with daily activities, overcoming physical obstacles at home and increased community access.
Read more: Helius Medical Technologies Inc ( HSM )

Translations provided by:
Français - Marc Bénita, Michel Cercueil, G Costas
Deutsch - Jojo Murer
Español - Marcos J. Diep
Italiano - Luca Ratti (frontend)
Русский язык - Vladimir, JanRUmoN Team
Nederlands - Daniel van Keulen
Dansk - Jakob Dalsgaard (frontend)
Język Polski - Leszek Boroch
Norsk (bokmål) - Goran Aasen
Português (Brasil) - Bernd R

 

Translations provided by:
Français - Marc Bénita, Michel Cercueil, G Costas
Deutsch - Jojo Murer
Español - Marcos J. Diep
Italiano - Luca Ratti (frontend)
Русский язык - Vladimir, JanRUmoN Team
Nederlands - Daniel van Keulen
Dansk - Jakob Dalsgaard (frontend)
Język Polski - Leszek Boroch
Norsk (bokmål) - Goran Aasen
Português (Brasil) - Bernd R

Translations provided by:
Français - Marc Bénita, Michel Cercueil, G Costas
Deutsch - Jojo Murer
Español - Marcos J. Diep
Italiano - Luca Ratti (frontend)
Русский язык - Vladimir, JanRUmoN Team
Nederlands - Daniel van Keulen
Dansk - Jakob Dalsgaard (frontend)
Język Polski - Leszek Boroch
Norsk (bokmål) - Goran Aasen
Português (Brasil) - Bernd R

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker